| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to a novel crystalline form of an inhibitor of the sodium-dependent glucose cotransporter SGLT2 of formula, characterised by a powder X-ray diffraction pattern (XRDP) with the application of CuKradiation, including peaks at 11.2, 12.9, 15.5, 17.8, 19.1, 20.0 and 20.7 degrees 2? (±0.1 degree 2?), spectrum of Raman scattering, including peaks at 353, 688, 825, 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm, as well as an endotherm, obtained by the method of differential scanning calorimetry (DSC), at 136°C, its obtaining by re-crystallisation from ethanol or methanol by the addition of water and based on it pharmaceutical compositions for treating diseases, the pathogenesis of which requires the inhibition of the sodium-dependent glucose cotransporter 2 (SGLT2).EFFECT: claimed is the novel crystalline form of the biologically active substance with low hygroscopicity.33 cl, 8 dwg, 5 tbl, 12 ex |
